

Elizabeth M Oliva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1589640/publications.pdf>

Version: 2024-02-01

32
papers

1,004
citations

516710

16
h-index

501196

28
g-index

32
all docs

32
docs citations

32
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and applications of the Veterans Health Administration's Stratification Tool for Opioid Risk Mitigation (STORM) to improve opioid safety and prevent overdose and suicide.. Psychological Services, 2017, 14, 34-49.	1.5	145
2	Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, The, 2020, 368, m283.	6.0	138
3	Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them. Current Psychiatry Reports, 2011, 13, 374-381.	4.5	125
4	Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S168-S179.e4.	1.5	70
5	Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers.. Psychological Services, 2013, 10, 410-419.	1.5	66
6	Receipt of opioid agonist treatment in the Veterans Health Administration: Facility and patient factors. Drug and Alcohol Dependence, 2012, 122, 241-246.	3.2	54
7	Trends in Opioid Agonist Therapy in the Veterans Health Administration: Is Supply Keeping up with Demand?. American Journal of Drug and Alcohol Abuse, 2013, 39, 103-107.	2.1	49
8	Trends in naloxone prescriptions prescribed after implementation of a National Academic Detailing Service in the Veterans Health Administration: A preliminary analysis. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S68-S72.	1.5	48
9	Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs. Substance Abuse, 2016, 37, 118-126.	2.3	34
10	Opioid Prescribing and Opioid Risk Mitigation Strategies in the Veterans Health Administration. Journal of General Internal Medicine, 2020, 35, 927-934.	2.6	34
11	Enhancing access to alcohol use disorder pharmacotherapy and treatment in primary care settings: ADaPT-PC. Implementation Science, 2015, 11, 64.	6.9	28
12	Article Commentary: Randomized Program Evaluation of the Veterans Health Administration Stratification Tool for Opioid Risk Mitigation (STORM): A Research and Clinical Operations Partnership to Examine Effectiveness. Substance Abuse, 2019, 40, 14-19.	2.3	25
13	Medical Providers' Knowledge and Concerns about Opioid Overdose Education and Take-Home Naloxone Rescue Kits within Veterans Affairs Health Care Medical Treatment Settings. Substance Abuse, 2017, 38, 135-140.	2.3	24
14	Implementing alcohol use disorder pharmacotherapy in primary care settings: a qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addiction Science & Clinical Practice, 2019, 14, 24.	2.6	24
15	Overdose Risk Associated with Opioid Use upon Hospital Discharge in Veterans Health Administration Surgical Patients. Pain Medicine, 2019, 20, 1020-1031.	1.9	22
16	Opioid Use and Its Relationship to Cardiovascular Disease and Brain Health: A Presidential Advisory From the American Heart Association. Circulation, 2021, 144, e218-e232.	1.6	20
17	Tracking implementation strategies in the randomized rollout of a Veterans Affairs national opioid risk management initiative. Implementation Science, 2020, 15, 48.	6.9	16
18	Correlates of Specialty Substance Use Disorder Treatment Among Female Patients in the Veterans Health Administration. Journal of Social Work Practice in the Addictions, 2012, 12, 282-301.	0.7	13

#	ARTICLE	IF	CITATIONS
19	Datapoints: False Starts in Psychotherapy for Substance Use Disorders and PTSD in the VHA. <i>Psychiatric Services</i> , 2013, 64, 722-722.	2.0	12
20	Opioid Discontinuation Among Patients Receiving High-Dose Long-Term Opioid Therapy in the Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2020, 35, 903-909.	2.6	10
21	Does following research-derived practice guidelines improve opiate-dependent patients' outcomes under everyday practice conditions? Results of the Multisite Opiate Substitution Treatment study. <i>Journal of Substance Abuse Treatment</i> , 2008, 34, 173-179.	2.8	9
22	Effect of a Predictive Analytics-Targeted Program in Patients on Opioids: a Stepped-Wedge Cluster Randomized Controlled Trial. <i>Journal of General Internal Medicine</i> , 2023, 38, 375-381.	2.6	8
23	Adolescent Substance Use Groups: Antecedent and Concurrent Personality Differences in a Longitudinal Study. <i>Journal of Personality</i> , 2012, 80, 769-793.	3.2	7
24	If pharmacotherapies for alcohol use disorders are effective, why are they underutilised?. <i>Evidence-Based Medicine</i> , 2014, 19, 230-231.	0.6	6
25	Comparison of naloxone prescribing patterns due to educational outreach conducted by full-time and part-time academic detailers at the U.S. Veterans Health Administration. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2020, 60, 639-646.	1.5	6
26	Extended Release Naltrexone for Alcohol Use Disorders: Quasi-Experimental Effects on Mortality and Subsequent Detoxification Episodes. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 79-83.	2.4	5
27	Randomized Policy Evaluation of the Veterans Health Administration Stratification Tool for Opioid Risk Mitigation (STORM). <i>Journal of General Internal Medicine</i> , 2022, 37, 3746-3750.	2.6	4
28	The Future of Social Network Analysis of Health Care System Data: Promise and Concerns. <i>Journal of General Internal Medicine</i> , 2016, 31, 142-143.	2.6	1
29	Naloxone Dispensing in Patients at Risk for Opioid Overdose After Total Knee Arthroplasty Within the Veterans Health Administration. , 2022, 39, 64-69.		1
30	Commentary on Geels <i>et al</i> . (2012): The search for G spurs questions about E. <i>Addiction</i> , 2012, 107, 528-529.	3.3	0
31	Commentary on Rege <i>et al</i> . (2018): Naloxone reports to US poison centers highlight overdose prevention opportunities. <i>Addiction</i> , 2018, 113, 2316-2317.	3.3	0
32	Commentary on Park <i>et al</i> . (2020): Buprenorphine and benzodiazepine co-prescribing—key considerations and future directions. <i>Addiction</i> , 2020, 115, 933-934.	3.3	0